Key Takeaways
- • Petrichor appoints Paul J. Sekhri as Operating Partner, adding a 35+ year life sciences executive to strengthen portfolio support capabilities across biotech and pharmaceutical sectors.
- • Sekhri currently serves as Chairman, President, and CEO of vTv Therapeutics while maintaining board seats at over 40 public and private companies, including Veeva Systems, Deep Genomics, and chairmanships at Resolution Therapeutics and Violet Therapeutics.
- • Petrichor has completed more than 125 healthcare investments with over $6 billion in deployed capital, positioning the firm as a significant player in growth-focused life sciences private investment.
- • Sekhri's extensive background spans leadership roles at eGenesis, Lycera Corporation, Cerimon Pharmaceuticals, and major pharmaceutical firms including Sanofi, Teva, Novartis, and ARIAD Pharmaceuticals, providing deep operational expertise across biotech and large-cap pharma.
- • The appointment reflects Petrichor's strategy to enhance operational and strategic support for portfolio companies across all development stages in healthcare innovation.
Summary
Petrichor, a growth-focused healthcare and life sciences private investment firm, has appointed Paul J. Sekhri as Operating Partner, signaling the firm's commitment to deepening operational support across its portfolio. Sekhri brings more than 35 years of accumulated experience across biotech and pharmaceutical sectors, positioning him as a seasoned industry veteran capable of providing board-level guidance and strategic counsel to portfolio companies.
Sekhri's current role includes serving as Chairman, President, and CEO of vTv Therapeutics. Beyond this executive position, he maintains an extensive board presence across the life sciences ecosystem, holding seats on more than 40 public and private company boards. His board positions include Veeva Systems, a leading cloud-computing provider to the life sciences industry, Kayothera, and Deep Genomics, alongside chairmanships at Resolution Therapeutics and Violet Therapeutics. This multi-board portfolio demonstrates his recognized value as a governance and strategic resource within institutional and emerging life sciences enterprises.
Prior to his current vTv role, Sekhri held senior leadership positions at multiple biotech firms, including eGenesis, Lycera Corporation, and Cerimon Pharmaceuticals. His experience also extends into the global pharmaceutical sector through strategic roles at Sanofi, Teva, TPG Biotech, ARIAD Pharmaceuticals, and Novartis—representing exposure to both mid-stage biotech operations and large-cap pharmaceutical environments. This breadth of experience across company sizes and development stages provides Sekhri with operational insight into scaling challenges and organizational complexity across the life sciences value chain.
Petrichor Founder and Managing Partner Tadd Wessel characterized Sekhri's appointment as a strategic enhancement, noting that Sekhri represents "a proven leader across biotech and big pharma whose expertise will strengthen our ability to support healthcare innovators at all stages of development." The firm has completed over 125 healthcare investments to date, deploying more than $6 billion in capital with extensive board representation across its portfolio. Sekhri's operating partner role aligns with institutional investor expectations that active private investment firms maintain deep operational resources to bridge portfolio companies' execution challenges between funding rounds.
Sekhri's current role includes serving as Chairman, President, and CEO of vTv Therapeutics. Beyond this executive position, he maintains an extensive board presence across the life sciences ecosystem, holding seats on more than 40 public and private company boards. His board positions include Veeva Systems, a leading cloud-computing provider to the life sciences industry, Kayothera, and Deep Genomics, alongside chairmanships at Resolution Therapeutics and Violet Therapeutics. This multi-board portfolio demonstrates his recognized value as a governance and strategic resource within institutional and emerging life sciences enterprises.
Prior to his current vTv role, Sekhri held senior leadership positions at multiple biotech firms, including eGenesis, Lycera Corporation, and Cerimon Pharmaceuticals. His experience also extends into the global pharmaceutical sector through strategic roles at Sanofi, Teva, TPG Biotech, ARIAD Pharmaceuticals, and Novartis—representing exposure to both mid-stage biotech operations and large-cap pharmaceutical environments. This breadth of experience across company sizes and development stages provides Sekhri with operational insight into scaling challenges and organizational complexity across the life sciences value chain.
Petrichor Founder and Managing Partner Tadd Wessel characterized Sekhri's appointment as a strategic enhancement, noting that Sekhri represents "a proven leader across biotech and big pharma whose expertise will strengthen our ability to support healthcare innovators at all stages of development." The firm has completed over 125 healthcare investments to date, deploying more than $6 billion in capital with extensive board representation across its portfolio. Sekhri's operating partner role aligns with institutional investor expectations that active private investment firms maintain deep operational resources to bridge portfolio companies' execution challenges between funding rounds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.